We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Nexavar

News List

Merck & Co.'s Keytruda cleared by FDA for certain treatment-experienced patients with HCC pharmafile
November 12, 2018
Merck & Co. on Friday said Keytruda (pembrolizumab) has received accelerated approval from the FDA for the treatment of hepatocellular carcinoma (HCC) in patients
Bayer plea for stay on compulsory license dismissed biospectrumasia
October 12, 2018
Bayer plea for stay on compulsory license dismissed
Sorafenib improves progression-free survival for patients with rare sarcomas europeanpharmaceuticalreview
April 03, 2018
A randomised clinical trial shows that the drug sorafenib tosylate extended progression-free survival compared with a placebo…
NICE bars NHS access to Lenvima, Nexavar for thyroid cancer pharmatimes
October 24, 2017
NHS treatment cost regulators have published draft guidelines rejecting funding for Eisai’s Lenvima and Bayer’s Nexavar for treating certain patients with thyroid cancer.
Nexavar receives final appraisal for primary liver cancer europeanpharmaceuticalreview
August 11, 2017
NICE has released a Final Appraisal Document recommending Nexavar for the treatment of patients with advanced hepatocellular carcinoma…